Treatment of eyelid tumors using ultrapulse carbon dioxide laser
Efficacy and Safety of Ultrapulse Carbon Dioxide Laser Treatment in Eyelid Tumors
This study tests whether using a special carbon dioxide laser to remove eyelid tumors is safe and effective for people with different types of eyelid growths.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Locations | 1 site (Guanzhou) |
| Trial ID | NCT06206681 on ClinicalTrials.gov |
What this trial studies
This study evaluates the long-term efficacy and safety of ultrapulse carbon dioxide (CO₂) laser excision for treating various eyelid tumors, including xanthelasma, pigmented nevi, and keratoses. It involves a retrospective analysis of 1000 patients diagnosed with these eyelid lesions who have undergone the laser treatment. The study aims to provide clinical guidance and decision support by assessing the effectiveness of this laser technique on different types of eyelid lesions.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with eyelid lesions such as xanthelasma, pigmented nevi, or keratoses who meet the inclusion criteria.
Not a fit: Patients with active infections in the target area, allergies to lidocaine, or those who are keloid-prone may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a safe and effective option for patients with eyelid tumors, improving cosmetic outcomes and reducing recurrence rates.
How similar studies have performed: Other studies have shown promising results with laser treatments for similar conditions, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinically diagnosed with eyelid lesions, including xanthelasma, pigmented nevi, keratoses, and so on. * No history of photosensitivity, bleeding, or coagulation disorders * Willing to attend follow-up appointments as scheduled Exclusion Criteria: * Presence of infection in the target area * Allergy to lidocaine * Keloid-prone or poor skin repair ability * Pregnant or lactating * Recent history of severe infectious diseases, active skin diseases, or major diseases affecting the cardiovascular, liver, kidney, endocrine, and hematopoietic systems * History of malignant tumors or immune system disorders
Where this trial is running
Guanzhou
- Sun Yat-sen University — Guanzhou, China (Recruiting)
Study contacts
- Principal investigator: Xianchai Lin, PhD — Zhongshan Ophthalmic Center, Sun Yat-sen University
- Study coordinator: Dingqiao Wang, PhD
- Email: wangdingqiao@163.com
- Phone: 13976031334
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.